ShRNA (short hairpin Ribonucleic Acid) recombinant plasmid of targeting Syt6 and application of shRNA recombinant plasmid in preparing PD (Parkinson's disease) treatment medicine

By constructing a shRNA recombinant plasmid targeting Syt6, knocking out the syt6 protein by using viral interference methods, the problem of loss of dopaminergic neurons in Parkinson's disease treatment was solved, improving the motor function of PD mice and increasing the dopaminergic neurons. Survival provides new therapeutic drug preparation pathways.

CN119061072APending Publication Date: 2024-12-03ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411489631.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-24
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Currently, there is a lack of effective treatment methods to prevent or delay the progress of Parkinson's disease (PD), and patients may be resistant to dopaminergic drugs. In the prior art, the method of targeting Syt6 shRNA recombinant plasmids for PD treatment has been rarely reported.

Method used

Design and construct shRNA recombinant plasmids targeting Syt6, and use siRNA target sequence design, primer combination, double-stranded oligo fragment annealing and ligation into a linearized RNA interference vector, replace the original ccdB toxic gene, and the recombinant products are screened and sequencing verification, a shRNA recombinant plasmid targeting Syt6 was obtained, which was used to knock out the expression of syt6 protein in the substantia nigra through viral interference methods.

Benefits of technology

Through the application of shRNA recombinant plasmid targeting Syt6, the motor function of PD mice can be improved and the survival of dopaminergic neurons in the substantia nigra, providing a new method for preparing PD therapeutic drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061072A_ABST
    Figure CN119061072A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to a ShRNA recombinant plasmid targeting Syt6 and application of the shRNA recombinant plasmid in preparation of a PD treatment medicine. The shRNA recombinant plasmid targeting the Syt6 is constructed by the following method: (1) designing a siRNA target sequence marked as Y19877 according to a Syt6 gene, and designing a corresponding primer combination; and (2) annealing the synthesized primer group into a double-chain oligo fragment, connecting the double-chain oligo fragment into a double-enzyme-digestion linearized RNA interference vector, replacing the original ccdB toxic gene, screening a recombinant product, carrying out sequencing verification, and carrying out plasmid extraction to obtain the shRNA recombinant plasmid targeting Syt6. The obtained shRNA recombinant plasmid targeting the Syt6 can interfere with the expression of the Syt6 gene, improve the motor function of PD mice and increase the survival of dopaminergic neurons in nigra, and can be used for preparing medicines for preventing and treating PD.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to a shRNA recombinant plasmid targeting Syt6 and an application thereof in preparing a PD therapeutic drug. Background Art

[0002] Parkinson's disease (PD) is one of the most common neurodegenerative diseases, accounting for more than 2% of people over 60 years old. The occurrence of PD is related to the degeneration and death of dopaminergic neurons in the substantia nigra. PD patients show motor symptoms and non-motor symptoms, which leads to a serious decline in patients' social and living abilities, and seriously increases the burden on patients, caregivers and the medical and health system. The main treatment for PD is currently drug therapy, which aims to reduce the loss of brain dopaminergic neurons by using the dopamine (DA) precursor L-DOPA, some dopaminergic agonists, and other drugs that indirectly increase dopamine (i.e., dopamine replacement therapy).

[0003] Dopaminergic replacement therapy can improve patients' quality of life, however, as the disease progresses, non-motor and motor symptoms appear, and patients may become resistant to dopaminergic drugs. Currently, there is no treatment that can prevent PD or slow its progression.

[0004] RNA interference (RNAi) refers to the phenomenon of highly conserved, highly efficient and specific degradation of homologous mRNA induced by double-stranded RNA (dsRNA) during evolution. Since the use of RNAi technology can specifically reduce or shut down the expression of specific genes, this technology has been widely used in the field of gene therapy for exploring gene functions and infectious diseases and malignant tumors. As a method of RNA interference, shRNA is a DNA molecule that transcribes short interfering RNA (siRNA, 19-21 nucleotide RNA double strands) using RNA polymerase III (pol III) promoters such as human and mouse U6 and H1. The shRNA transcribed in the cell is processed and incorporated into the RNA-induced silencing complex (RISC), which guides the nuclease to degrade the target RNA.

[0005] The advantage of shRNA expression vectors is that they can be used for long-term research - vectors with antibiotic markers can continuously inhibit the expression of target genes in cells for several weeks or even longer. Viral vectors can also be used for siRNA expression. Their advantage is that they can directly infect cells with high efficiency for gene silencing research, avoiding the inconvenience caused by low plasmid transfection efficiency, and the transfection effect is more stable.

[0006] Currently, there are few reports on the construction of shRNA recombinant plasmids targeting Syt6 (synaptotagmin 6) and their use in the prevention and treatment of PD. Summary of the invention

[0007] In view of the shortcomings and deficiencies of the above prior art, the primary purpose of the present invention is to provide a shRNA recombinant plasmid targeting Syt6.

[0008] Another object of the present invention is to provide the use of the above-mentioned Syt6-targeting shRNA recombinant plasmid in the preparation of PD therapeutic drugs.

[0009] The purpose of the present invention is achieved through the following technical solutions:

[0010] A shRNA recombinant plasmid targeting Syt6 was constructed by the following method:

[0011] (1) Design the following Y19877 siRNA target sequence based on the Syt6 gene, and design the corresponding primer combination;

[0012] Y19877 GCGGAAGTTTCTGACCCTTA(SEQ ID NO:1);

[0013] (2) The synthesized primer set was annealed into a double-stranded oligo fragment, which was then connected to a double-enzyme-cut linearized RNA interference vector to replace the original ccdB toxic gene. The recombinant product was screened and sequenced, and then the plasmid was extracted to obtain a Syt6-targeting shRNA recombinant plasmid.

[0014] Furthermore, the primer set for the target sequence Y19877 is Y19877-F and Y19877-R, and their sequences are as follows:

[0015] Y19877-F ACCGGCGGAAGTTCTGACCCTTATTCAAGAGATAAGGGTCAGAACTTC

[0016] CGCTTTTTTg (SEQ ID NO: 3);

[0017] Y19877-R CTAGCAAAAAAGCGGAAGTTCTGACCCTTATCTCTTGAATAAGGGTCA

[0018] GAACTTCCGC (SEQ ID NO: 4).

[0019] Furthermore, the step of annealing the synthesized primer set into a double-stranded oligo fragment in step (2) is as follows:

[0020] The synthesized single-stranded primers were dissolved in oligo annealing buffer, and the complementary single-stranded oligos were mixed. The resulting oligo mixture was heated at 95°C in a water bath for 5 min and cooled naturally to room temperature to form double-stranded oligo fragments.

[0021] Furthermore, the RNA interference vector in step (2) is pAAV-U6-shRNA / spgRNA v2.0-CMV-

[0022] EGFP-WPRE vector. Its plasmid map is as follows Figure 1 shown.

[0023] Furthermore, the preparation method of the double-enzyme-digested linearized RNA interference vector is as follows:

[0024] The expression vector was digested with restriction endonuclease BsmBI, and the digestion product was subjected to agarose gel electrophoresis to detect the digestion effect. The target vector band was cut out from the gel after agarose gel electrophoresis and gel recovered to obtain a double-digested linearized RNA interference vector.

[0025] Furthermore, the ligation reaction system for ligating the double-stranded oligo fragment into the double-enzyme-digested linearized RNA interference vector in step (2) is as follows:

[0026] Double-stranded oligo fragment 10mM 1μl;

[0027] Linearized RNA interference vector 40ng / μl 3μl;

[0028] 10×T4 DNA ligase buffer 2 μl;

[0029] T4 DNA ligase 1 μl;

[0030] dd 2 0 to 20 μl.

[0031] Furthermore, the steps of screening the recombinant product in step (2) are as follows:

[0032] The recombinant product was transformed into DH5α competent cells, positive transformants were identified by colony PCR, positive transformants were sequenced and verified, the sequencing results were analyzed, and positive clones that were correctly verified by sequencing were selected.

[0033] Application of the above-mentioned Syt6-targeting shRNA recombinant plasmid in the preparation of PD therapeutic drugs.

[0034] Compared with the prior art, the present invention has the following beneficial effects:

[0035] (1) The present invention designs a shRNA interference fragment targeting Syt6. The interference fragment is constructed into a specific expression vector by molecular biological means, and the vector can interfere with the Syt6 gene. In addition to being able to directly transiently transfect cells for interference with the Syt6 gene, the vector can also be packaged with adeno-associated viruses to interfere with the expression of the Syt6 gene at the animal level.

[0036] (2) The Syt6-targeting shRNA recombinant plasmid obtained in the present invention can knock out the expression of syt6 protein in the substantia nigra of PD by viral interference, which can improve the motor function of PD mice and increase the survival of dopaminergic neurons in the substantia nigra, and can be used for the preparation of drugs for the prevention and treatment of PD. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 This is the plasmid map of the pAAV-U6-shRNA / spgRNA v2.0-CMV-EGFP-WPRE vector used in the present invention.

[0038] Figure 2 This is a diagram showing the results of animal model testing of the Syt6-targeting shRNA recombinant plasmid Y19877 obtained in the present invention in the treatment of PD mice. DETAILED DESCRIPTION

[0039] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.

[0040] Example 1

[0041] A method for constructing a shRNA recombinant plasmid targeting Syt6 comprises the following steps:

[0042] (1) Interference target design and primer synthesis:

[0043] The following siRNA target sequence Y19877 and NC control Y9957 containing an unrelated sequence were designed based on the Syt6 gene, and the corresponding primer sets Y19877-F / Y19877-R and Y9957-F / Y9957-R were designed and synthesized.

[0044] Y19877 GCGGAAGTTTCTGACCCTTA(SEQ ID NO:1);

[0045] Y9957 CCTAAGGTTAAGTCGCCCTCG (SEQ ID NO: 2);

[0046] Y19877-F ACCGGCGGAAGTTCTGACCCTTATTCAAGAGATAAGGGTCAGAACTTCCGCTTTTTTG (SEQ ID NO: 3);

[0047] Y19877-R CTAGCAAAAAAGCGGAAGTTCTGACCCTTATCTCTTGAATAAGGGGTCAGAACTTCCGC (SEQ ID NO: 4);

[0048] Y9957-F ACCGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGTTTTTTG (SEQ ID NO: 5);

[0049] Y9957-R CTAGCAAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG (SEQ ID NO: 6).

[0050] (2) Primers anneal to form double-stranded fragments with sticky ends:

[0051] Dissolve the synthesized primer sets into 20 μM using oligo annealing buffer, and mix 30 μl of each complementary single strand. Heat the oligo mixture in a water bath at 95°C for 5 min, then leave the water bath uncovered and cool naturally to room temperature to form double-stranded oligo fragments. Take 1 μl for subsequent ligation reaction, and store the rest at -20°C.

[0052] (3) Preparation of linearized expression vector:

[0053] The pAAV-U6-shRNA / spgRNA v2.0-CMV-EGFP-WPRE vector was used. Its plasmid map is shown in Figure 1 As shown. The expression vector was digested with restriction endonuclease BsmBI. The digestion reaction system was: 2μg of plasmid vector, 5μl of 10× reaction buffer, 1μl of each restriction endonuclease, and 50μl of deionized water. Incubate in a 37℃ water bath for more than 2h. The digestion product was subjected to agarose gel electrophoresis to detect the digestion effect, and the target vector band was cut out from the gel after agarose gel electrophoresis and recovered with TaKaRa MiniBEST Agarose Gel DNA Extraction Kit Ver.3.0. For specific steps, refer to the kit manual.

[0054] (4) Interference fragments are connected into expression vectors:

[0055] Double-stranded oligo fragment 10mM 1μl;

[0056] Linearized RNA interference vector 40ng / μl 3μl;

[0057] 10×T4 DNA ligase buffer 2 μl;

[0058] T4 DNA ligase 1 μl;

[0059] dd 2 0 to 20 μl.

[0060] Ligation was allowed to proceed overnight at 16°C.

[0061] (5) Transformation of competent cells:

[0062] Transform the recombinant product into DH5α competent cells. For details on the transformation of DH5α competent cells, please refer to the Concise Molecular Biology Experiment Guide.

[0063] (6) Colony PCR identification of positive transformants:

[0064] The transformants grown on the plate were picked and resuspended in 10 μl LB culture medium, and 1 μl was used as a template for colony PCR identification.

[0065] The reaction system and PCR cycle conditions are as follows:

[0066] PCR reaction mixture composition

[0067]

[0068] PCR reaction conditions

[0069] 3StepPCR

[0070]

[0071] (7) Send positive clones for sequencing:

[0072] The positive clones obtained by colony identification were sent to a sequencing company for sequencing verification. The sequencing results were compared and analyzed using Vector NTI software. The sequencing results of the obtained Y19877 and Y9957 recombinant plasmids were as follows:

[0073] Y19877 sequencing results:

[0074] CTGGGGATATTTGACTGTAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAAC ACCGGCGGAAGTTCTGACCCTTATTCAAGAGATAAGGGTC AGAACTTCCGCTTTTTTG CTAGCCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTT(SEQ ID NO:7).

[0075] Sequencing results of Y9957 (NC control plasmid containing a non - relevant sequence):

[0076] ATAGAAAATGGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGG CTAGCAAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGCGGTGTTCGTCCTTTCCACAAGATATATAAAGCCAAGAAATCGAAATACTTTCAAGTTACGGTAAGCATATGATAGTCCATTTTAAAACATAATTTTAAAACTGCAAACTACCCAAGAAATTATTACTTTCTACGTCACGTATTTTGTACTAATATCTTTGTGTTTACAGTCAAATTAATTCCAATTATCTCTCTAACAGCCTTGTATCGTATATGCAAATATGAAGGAATCATGGG AAATAGGCCCTCGGTGAAGGGGGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCGGCCTCAGTGAGCCAGCGAGCGCGCAGCTACCTTGCGGGACATGTGAGCAAAAGGCCAGCAAAAGGCCAGCAATCGTAAAAAGGCCGCGTATGCTGGCGTTTTTCCCTAGGCT (SEQ ID NO:8).

[0077] (8) Plasmid extraction:

[0078] After sequencing, the correct positive clones were verified and the plasmid was extracted. The specific steps are shown in the kit instructions.

[0079] The shRNA recombinant plasmid Y19877 targeting Syt6 obtained in this example is effective in the treatment of PD mice.

[0080] Animal model and grouping: Male C57BL / 6 mice (8 weeks old, 22-24 g) were obtained from Liaoning Changsheng Biotechnology Co., Ltd. (Liaoning, China). Before the experiment, all mice were housed at 20-22°C with a 12 h:12 h light / dark cycle, and food and water were available ad libitum for 7 days. A total of 84 male mice were randomly divided into 4 groups as follows: 1) MPTP+scramble control group (MPTP+scramble, received MPTP (Sigma-Aldrich, USA) (30 mg / kg) intraperitoneal injection for 5 days, and then 2 μl of empty virus Y9957 recombinant plasmid was injected into the midbrain by stereotaxic midbrain method to serve as a control group for detecting the blocking of Syt6 levels); 2) NC+scramble control group (NC+scramble, received saline (30 mg / kg) intraperitoneal injection for 5 days, and then 2 μl of empty virus Y9957 recombinant plasmid was injected into the midbrain by stereotaxic midbrain method to serve as a control group for detecting the blocking of Syt6 levels Control group); 3) MPTP+shRNA recombinant plasmid group targeting Syt6 (MPTP+syt6-shRNA, received MPTP intraperitoneal injection for 5 days, and then 2μl of shRNA recombinant plasmid viral vector Y19877 recombinant plasmid targeting Syt6 was injected into the midbrain through a stereotactic midbrain method to block the Syt6 level); 4) NC+shRNA recombinant plasmid group targeting Syt6 (NC+syt6-shRNA, intraperitoneal injection of normal saline (30mg / kg) for 5 days, and 2μl of shRNA recombinant plasmid viral vector Y19877 recombinant plasmid targeting Syt6 was injected into the midbrain through a stereotactic midbrain method to block the Syt6 level). Western Blot (WB) was used to detect the transfection efficiency of each group of mice, and the expression of tyrosine hydroxylase (TH) in the substantia nigra of each group of mice was detected by immunofluorescence, and the motor function of each group of mice was tested by a climbing pole experiment. The test results are as follows Figure 2 shown. Figure 2 A: Representative protein blot of Syt6 protein expression in the substantia nigra of each group of mice; B: Quantitative analysis of Syt6 protein expression in the substantia nigra of each group of mice; C: Quantification of the total time of each group of mice performing the pole climbing test; D: Immunofluorescence staining image of TH expression in the substantia nigra of each group of mice, scale bar, 100 μm; E: Quantitative analysis of TH immunostaining in the substantia nigra of each group of mice.

[0081] Depend on Figure 2The results showed that compared with the MPTP+scrambled control group, the expression of SYT6 / DAPI in the substantia nigra in the MPTP+SYT6-shRNA group was significantly reduced by 86.9%, and compared with the NC+scrambled control group, the expression of SYT6 / DAPI in the substantia nigra in the NC+SYT6-shRNA group was significantly reduced by 88.3%. After Syt6 was knocked out in the substantia nigra, the mice in the MPTP+Syt6-shRNA group showed significantly improved function in the pole climbing test ( Figure 2 Meanwhile, in MPTP-PD mice treated with syt6 AAV, TH expression increased significantly by 78.27%, while in NC mice treated with syt6 AAV, TH expression did not change significantly ( Figure 2 D and E). This indicates that SYT6 protein is a key protein in PD. Knocking out the expression of syt6 protein in the substantia nigra of PD using viral interference can improve the motor function of PD mice and increase the survival of dopaminergic neurons in the substantia nigra.

[0082] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A shRNA recombinant plasmid targeting Syt6, characterized in that: It is constructed by the following method: (1) Design the following Y19877 siRNA target sequence based on the Syt6 gene, and design the corresponding primer combination; Y19877 GCGGAAGTTTCTGACCCTTA(SEQ ID NO:1); (2) The synthesized primer set was annealed into a double-stranded oligo fragment, which was then connected to a double-enzyme-cut linearized RNA interference vector to replace the original ccdB toxic gene. The recombinant product was screened and sequenced, and then the plasmid was extracted to obtain a Syt6-targeting shRNA recombinant plasmid.

2. The shRNA recombinant plasmid targeting Syt6 according to claim 1, characterized in that: The primer set for the target sequence Y19877 is Y19877-F and Y19877-R, and their sequences are as follows: Y19877-F ACCGGCGGAAGTTCTGACCCTTATTCAAGAGATAAGGGTCAGAACTTCCGCTTTTTg(SEQID NO:3); Y19877-R CTAGCAAAAAAGCGGAAGTTCTGACCCTTATCTCTTGAATAAGGGGTCAGAACTTCCGC (SEQ ID NO: 4).

3. The shRNA recombinant plasmid targeting Syt6 according to claim 1, characterized in that: The step of annealing the synthesized primer set into a double-stranded oligo fragment in step (2) is as follows: The synthesized single-stranded primers were dissolved in oligo annealing buffer, and the complementary single-stranded oligos were mixed. The resulting oligo mixture was heated at 95°C in a water bath for 5 min and cooled naturally to room temperature to form double-stranded oligo fragments.

4. The shRNA recombinant plasmid targeting Syt6 according to claim 3, characterized in that: The RNA interference vector described in step (2) adopts pAAV-U6-shRNA / spgRNA v2.0-CMV-EGFP-WPRE vector.

5. The shRNA recombinant plasmid targeting Syt6 according to claim 4, characterized in that: The preparation method of the double-enzyme-digested linearized RNA interference vector is as follows: The expression vector was digested with restriction endonuclease BsmBI, and the digestion product was subjected to agarose gel electrophoresis to detect the digestion effect. The target vector band was cut out from the gel after agarose gel electrophoresis and gel recovered to obtain a double-digested linearized RNA interference vector.

6. The shRNA recombinant plasmid targeting Syt6 according to claim 5, characterized in that: The ligation reaction system for ligating the double-stranded oligo fragment into the double-enzyme-digested linearized RNA interference vector in step (2) is as follows: Double-stranded oligo fragment 10mM 1μl; Linearized RNA interference vector 40ng / μl 3μl; 10×T4 DNA ligase buffer 2 μl; T4 DNA ligase 1 μl; dd HO to 20 μl.

7. The shRNA recombinant plasmid targeting Syt6 according to claim 1, characterized in that: The steps of screening the recombinant product in step (2) are as follows: The recombinant product was transformed into DH5α competent cells, positive transformants were identified by colony PCR, positive transformants were sequenced and verified, the sequencing results were analyzed, and positive clones that were correctly verified by sequencing were selected.

8. Use of a Syt6-targeting shRNA recombinant plasmid according to any one of claims 1 to 7 in the preparation of PD therapeutic drugs.